[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541128":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":19,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Egyptian Liver Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Group 1",null,[12],"Diagnostic Test: General Evaluation Score (GES)",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","General Evaluation Score (GES)","According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \\>7.5 points)",[9],[20],{"facility":5,"status":10,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"Ţalkhā","Dakahlia Governorate","36681","Egypt","EG",{"type":27,"coordinates":28},"Point",[29,30],31.37787,31.0539,{"lat":30,"lon":29},{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100541128","the-study-of-the-validation-of-general-evaluation-score-ges-in-the-prediction-of-hepatocellular-carcinoma-risk-among-patients-with-advanced-fibrosis-and-cirrhosis-who-achieved-sustained-virological-response-for-hepatitis-c-virus-after-direct-acting-antiviral-drugs-100541128",false,"NCT06325826","The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4)\n* achieved SVR for HCV after DAAs.\n\nExclusion Criteria:\n\n* Previous interferon (IFN) treatment.\n* Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection.\n* Current hepatocellular carcinoma (HCC) or other malignancies.\n* Previous history of HCC or HCC intervention.\n* Liver cell failure, liver transplantation or renal impairment","ALL","18 Years",{"count":43,"type":44},500,"ACTUAL","OBSERVATIONAL","This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.",[48],"Hepatocellular Carcinoma","UNKNOWN","2024-03-22",{"date":52,"type":44},"2024-03-26",{"date":54,"type":44},"2022-02-01",{"date":56,"type":57},"2025-06-30","ESTIMATED",{"name":5,"class":6},1]